Working… Menu

Safety Study of Pritumumab in Brain Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04396717
Recruitment Status : Recruiting
First Posted : May 21, 2020
Last Update Posted : September 2, 2021
Hoag Memorial Hospital Presbyterian
Information provided by (Responsible Party):
Nascent Biotech

Tracking Information
First Submitted Date  ICMJE April 29, 2020
First Posted Date  ICMJE May 21, 2020
Last Update Posted Date September 2, 2021
Actual Study Start Date  ICMJE March 18, 2021
Estimated Primary Completion Date January 30, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 15, 2020)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: Up to 24 weeks ]
Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v.5.0 during first 24 weeks of treatment
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 15, 2020)
Intra-cranial Objective Response Rate [ Time Frame: 2 months ]
Intra-cranial objective response rate at 2 months as assessed by the Response Assessment in Neuro-oncology (RANO) criteria
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Safety Study of Pritumumab in Brain Cancer
Official Title  ICMJE A Phase 1, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Exposure of Pritumumab in Patients With Brain Cancer
Brief Summary

Pritumumab is a human IgG1 kappa antibody that binds to a malignant tumor associated antigen, ecto domain-vimentin (EDV) which is expressed in a variety of tumor cells. Pritumumab was shown to have relatively high reactivity with brain cancer cell lines, while no reactivity was demonstrated with normal neurons, astrocytes or fetal cerebral cells. Pritumumab has notable antibody-dependent cellular cytotoxicity (ADCC), brain tumor penetration and antitumor activity in nude mouse human xenograft models.

Primary Objectives

- To determine the safety and/or tolerability and the recommended Phase 2 dose (RP2D) of escalating, intravenously (IV) administered Pritumumab doses in patients with recurrent gliomas or with brain metastases.

Secondary Objectives

  • To determine pharmacokinetics and pharmacodynamics of Pritumumab
  • To identify preliminary signals of anti-tumor response to Pritumumab
  • To explore disease-related, patient-reported outcomes
Detailed Description

This is an open-label, Phase 1, outpatient, dose escalation study of Pritumumab in patients with brain cancer who have failed prior therapy and have no other available options. In the first part of the study, escalating doses of Pritumumab of 1.6, 4.8, 8.0, 12.0, and 16.2 mg/kg will be administered in a sequential, safety-driven manner to eligible patients according to standard 3+3 scheme, as an 1-hour IV infusion on Days 1, 8, 15, and 22 of each 28-day treatment cycle. The dose levels may be modified upon obtained results. Once the maximum tolerated dose (MTD) is determined, an expansion cohort including 6-12 patients in selected tumor type at a dose equal or below to MTD is planned to determine the recommended Phase 2 dose (RP2D). A total of 42 patients may be administered with Pritumumab in this study.

Patients will be treated with Pritumumab for a maximum of 6 cycles or until cancer progression or unacceptable toxicity. Patients will be followed after treatment completion every four months or until death or lost to follow-up. Standard clinical, laboratory and functional assessments will be employed to monitor for safety, tolerability and tumor response, including blood sampling for clinical biochemistries, pharmacokinetics, CSF and tissue samples, at frequency specified by the protocol. Patient-reported outcomes will also be assessed.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description:
Open label, non-randomized, 3+3 dose escalation to determine MTD, followed by exoansion to 6-12 patients to determine RP2D. Subjects will continue study treatment until progressive disease or unacceptable toxicity. Follow-up will occur until death or lost to follow-up.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Malignant Primary Brain Tumors
  • Brain Metastases, Adult
Intervention  ICMJE Biological: Pritumumab
Pritumumab IgG1 human monoclonal antibody
Study Arms  ICMJE Experimental: Pritumumab

Dose Escalation phase (3+3 patients):

Pritumumab administered sequentially as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at: 1.6 mg/kg, 4.8 mg/kg, 8.0 mg/kg, 12.0 mg/kg, and 16.2 mg/kg, for a maximum of 6 cycles or progression or unacceptable toxicity.

Expansion phase (6-12 patients): Pritumumab administered as 1-hour IV infusion, on Day 1, 8, and 22 of each 28-day treatment cycle at or below MTD for a maximum of 6 cycles or progression or unacceptable toxicity.

Intervention: Biological: Pritumumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 15, 2020)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 30, 2023
Estimated Primary Completion Date January 30, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria Subjects must meet all of the inclusion criteria to participate in this study.

  1. Ability to understand and the willingness to provide informed consent.
  2. Diagnosis

    Histologically confirmed diagnosis of brain cancer:

    • glioblastoma (GBM),
    • anaplastic astrocytoma (AA),
    • anaplastic oligodendroglioma (AO),
    • anaplastic mixed oligoastrocytoma (AMO),
    • low grade gliomas,
    • brain metastases,
    • meningiomas, chordomas, medulloblastoma, craniopharyngiomas, pituitary tumors or
    • leptomeningeal metastases
  3. Prior Therapy Has failed prior standard therapy including maximal safe surgical resection, radiation therapy (when appropriate for the specific cancer type), or systemic therapy or is intolerant of, or has refused other available therapies, but is still in need of therapy. No patients may receive Pritumumab prior to any surgery for their cerebral tumor
  4. Progression/Recurrence Has progression of brain cancer and measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan.

    For leptomeningeal metastases, positive cytology is acceptable if imaging is not measurable.

  5. Age Age ≥ 18 years.
  6. Performance Status Karnofsky Performance Status ≥ 60% (see Appendix A). Subjects must have a life expectancy of equal to or greater than 8 weeks.
  7. Organ and Marrow Function Requirements


    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • Platelet count ≥ 100 x 109/L
    • Hemoglobin ≥ 9.0 g/dL
    • White blood cell (WBC) count ≥ 3.0 x 109/L


    • AST/SGOT and ALT/SGPT ≤ 5 x institution's ULN
    • Total bilirubin ≤ 3 x institution's ULN
    • Serum creatinine ≤ 2 x institution's ULN or 24-hour creatinine clearance ≥ 50 mL/min
    • Alkaline phosphatase (ALP) ≤ 3 x ULN unless considered tumor related
    • Estimated GFR > 50 mL/min


    • INR ≤ 1.4
    • PT/aPTT ≤ 1.2 x institution's ULN
  8. Contraception All fertile females and any man with a partner of child-bearing potential agrees to use adequate contraception which will include two of the following: hormonal or barrier method of birth control, or abstinence prior to study entry, for the duration of study participation, and for 30 days following completion of therapy.
  9. Although Pritumumab shows notable immunohistologic reactivity against active endometrial tissues, fertile female patients will be included in this study.

Exclusion Criteria Subjects meeting any of the exclusion criteria at baseline will be excluded from study participation.

  1. Current or anticipated use of other investigational agents.
  2. Insufficient time for recovery from prior therapy:

    • less than 28 days from any prior cytotoxic investigational agent,
    • less than 14 days from any prior non-cytotoxic investigational agent,
    • less than 28 days from prior cytotoxic therapy (except 23 days from prior temozolomide at 5 day regimen and 14 days from prior temozolomide at daily regimen, 14 days from vincristine, 42 days from nitrosoureas, 21 days from procarbazine administration),
    • less than 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, targeted therapies (radiosensitizer does not count),
    • less than 7 days for immunotherapy agents, e.g., DCVax, Celldex, PD1, etc.
  3. Less than 3 weeks from surgery or insufficient recovery from surgical-related trauma or wound healing.
  4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Pritumumab plus any patently atopic patients who have a history of having experienced an episode of allergic anaphylaxis.
  5. Severe or uncontrolled medical disorder that would, in the investigator's opinion, impair ability to receive study treatment (i.e., uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active, uncontrolled infection).
  6. Known diagnosis of human immunodeficiency virus (HIV) infection.
  7. Impaired cardiac function including any of the following:

    • Congenital long QT syndrome or a known family history of long QT syndrome;
    • History or presence of clinically significant ventricular or atrial tachyarrhythmias
    • Clinically significant resting bradycardia (< 50 beats per minute)
    • Inability to monitor the QT interval by ECG
    • QTc > 450 msec on baseline ECG. If QTc > 450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
    • Myocardial infarction within 1 year of starting study drug
    • Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
  8. Any female patients who develop serious uterine hemorrhage during this study may need to be excluded from further treatment with Pritumumab.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Deborah Fridman, PSD, RN 949.764.4430
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT04396717
Other Study ID Numbers  ICMJE 08091967
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Nascent Biotech
Study Sponsor  ICMJE Nascent Biotech
Collaborators  ICMJE Hoag Memorial Hospital Presbyterian
Investigators  ICMJE
Principal Investigator: Jose A. Carrillo, MD One Hoag Drive Newport Beach, CA 92663, United States
PRS Account Nascent Biotech
Verification Date August 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP